349 related articles for article (PubMed ID: 16195703)
1. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer.
Ghosh A; Allamarvdasht M; Pan CJ; Sun MS; Mansfield BC; Byrne BJ; Chou JY
Gene Ther; 2006 Feb; 13(4):321-9. PubMed ID: 16195703
[TBL] [Abstract][Full Text] [Related]
2. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.
Koeberl DD; Sun BD; Damodaran TV; Brown T; Millington DS; Benjamin DK; Bird A; Schneider A; Hillman S; Jackson M; Beaty RM; Chen YT
Gene Ther; 2006 Sep; 13(17):1281-9. PubMed ID: 16672983
[TBL] [Abstract][Full Text] [Related]
3. Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors.
Beaty RM; Jackson M; Peterson D; Bird A; Brown T; Benjamin DK; Juopperi T; Kishnani P; Boney A; Chen YT; Koeberl DD
Gene Ther; 2002 Aug; 9(15):1015-22. PubMed ID: 12101432
[TBL] [Abstract][Full Text] [Related]
4. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia.
Koeberl DD; Pinto C; Sun B; Li S; Kozink DM; Benjamin DK; Demaster AK; Kruse MA; Vaughn V; Hillman S; Bird A; Jackson M; Brown T; Kishnani PS; Chen YT
Mol Ther; 2008 Apr; 16(4):665-72. PubMed ID: 18362924
[TBL] [Abstract][Full Text] [Related]
5. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
Lee YM; Jun HS; Pan CJ; Lin SR; Wilson LH; Mansfield BC; Chou JY
Hepatology; 2012 Nov; 56(5):1719-29. PubMed ID: 22422504
[TBL] [Abstract][Full Text] [Related]
6. Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice.
Sun MS; Pan CJ; Shieh JJ; Ghosh A; Chen LY; Mansfield BC; Ward JM; Byrne BJ; Chou JY
Hum Mol Genet; 2002 Sep; 11(18):2155-64. PubMed ID: 12189168
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.
Sun B; Zhang H; Franco LM; Young SP; Schneider A; Bird A; Amalfitano A; Chen YT; Koeberl DD
Mol Ther; 2005 Jan; 11(1):57-65. PubMed ID: 15585406
[TBL] [Abstract][Full Text] [Related]
8. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054
[TBL] [Abstract][Full Text] [Related]
9. Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector.
Luo X; Hall G; Li S; Bird A; Lavin PJ; Winn MP; Kemper AR; Brown TT; Koeberl DD
Mol Ther; 2011 Nov; 19(11):1961-70. PubMed ID: 21730973
[TBL] [Abstract][Full Text] [Related]
10. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain.
Broekman ML; Comer LA; Hyman BT; Sena-Esteves M
Neuroscience; 2006; 138(2):501-10. PubMed ID: 16414198
[TBL] [Abstract][Full Text] [Related]
11. Rescue administration of a helper-dependent adenovirus vector with long-term efficacy in dogs with glycogen storage disease type Ia.
Crane B; Luo X; Demaster A; Williams KD; Kozink DM; Zhang P; Brown TT; Pinto CR; Oka K; Sun F; Jackson MW; Chan L; Koeberl DD
Gene Ther; 2012 Apr; 19(4):443-52. PubMed ID: 21654821
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a.
Chou JY; Zingone A; Pan CJ
Eur J Pediatr; 2002 Oct; 161 Suppl 1():S56-61. PubMed ID: 12373573
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia.
Koeberl DD; Sun B; Bird A; Chen YT; Oka K; Chan L
Mol Ther; 2007 Jul; 15(7):1253-8. PubMed ID: 17505475
[TBL] [Abstract][Full Text] [Related]
15. An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia.
Zhang L; Cho JH; Arnaoutova I; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):470-479. PubMed ID: 30714174
[TBL] [Abstract][Full Text] [Related]
16. AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect.
Su H; Huang Y; Takagawa J; Barcena A; Arakawa-Hoyt J; Ye J; Grossman W; Kan YW
Gene Ther; 2006 Nov; 13(21):1495-502. PubMed ID: 16775632
[TBL] [Abstract][Full Text] [Related]
17. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
Sun B; Zhang H; Franco LM; Brown T; Bird A; Schneider A; Koeberl DD
Mol Ther; 2005 Jun; 11(6):889-98. PubMed ID: 15922959
[TBL] [Abstract][Full Text] [Related]
18. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia.
Zhang L; Lee C; Arnaoutova I; Anduaga J; Starost MF; Mansfield BC; Chou JY
Biochem Biophys Res Commun; 2020 Jun; 527(3):824-830. PubMed ID: 32430177
[TBL] [Abstract][Full Text] [Related]
20. Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy.
Yiu WH; Lee YM; Peng WT; Pan CJ; Mead PA; Mansfield BC; Chou JY
Mol Ther; 2010 Jun; 18(6):1076-84. PubMed ID: 20389290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
